Revenue: As of FY2026 Q1, the actual value is USD 935.4 M, beating the estimate of USD 922.94 M.EPS: As of FY2026 Q1, the actual value is USD 0.97, beating the estimate of USD 0.9067.EBIT: As of FY2026 Q1, the actual value is USD 156.4 M.<h3>Mobile Solutions Segment</h3><ul><li>Net Sales: $598.3 million for the three months ended October 31, 2025, compared to $572.4 million for the same period in 2024, an increase of $25.9 million or 4.5%.</li><li>Earnings Before Income Taxes: $111.3 million, representing 18.6% of net sales, up from 18.3% in the prior year.</li></ul><h3>Industrial Solutions Segment</h3><ul><li>Net Sales: $257.8 million for the three months ended October 31, 2025, compared to $257.6 million for the same period in 2024, an increase of $0.2 million or 0.1%.</li><li>Earnings Before Income Taxes: $32.2 million, representing 12.5% of net sales, down from 15.9% in the prior year.</li></ul><h3>Life Sciences Segment</h3><ul><li>Net Sales: $79.3 million for the three months ended October 31, 2025, compared to $70.1 million for the same period in 2024, an increase of $9.2 million or 13.1%.</li><li>Earnings Before Income Taxes: $7.3 million, representing 9.2% of net sales, up from a loss of 7.6% in the prior year.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: $125.4 million for the three months ended October 31, 2025, compared to $72.9 million for the same period in 2024, an increase of $52.5 million.</li><li>Investing Activities: Cash used was $3.4 million, compared to $96.0 million in the prior year, primarily due to the equity method investment in Medica during the previous year.</li><li>Financing Activities: Cash used was $93.1 million, compared to cash provided of $9.8 million in the prior year, primarily driven by a decrease in short-term borrowings and increased share repurchases.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue leveraging its global manufacturing footprint and supply chain to mitigate the cost impact of tariffs, with expected annual costs related to tariffs of approximately $25 million, down from $35 million previously.</li><li>Non-Core Business: The company is focused on restructuring activities to improve operating and manufacturing cost structures, with estimated future costs associated with these actions ranging from $5.0 million to $10.0 million through fiscal 2026.</li></ul>

Donaldson | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 935.4 M